Neo Ivy Capital Management Has $1.40 Million Stock Holdings in Insmed, Inc. $INSM

Neo Ivy Capital Management decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 43.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,688 shares of the biopharmaceutical company’s stock after selling 7,568 shares during the quarter. Neo Ivy Capital Management’s holdings in Insmed were worth $1,395,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Stone House Investment Management LLC acquired a new position in Insmed during the third quarter worth $29,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its position in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares during the period. Finally, AlphaQuest LLC grew its holdings in Insmed by 109.5% during the third quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 150 shares during the last quarter.

Insmed Stock Performance

NASDAQ INSM opened at $140.13 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The firm has a market capitalization of $30.21 billion, a price-to-earnings ratio of -21.86 and a beta of 1.13. The company’s fifty day moving average is $158.58 and its two-hundred day moving average is $165.58. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) EPS. The business’s revenue for the quarter was up 152.6% compared to the same quarter last year. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity

In other news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. This trade represents a 5.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider owned 41,754 shares of the company’s stock, valued at $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 189,651 shares of company stock worth $31,784,545 over the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on INSM. Cantor Fitzgerald lifted their price target on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. The Goldman Sachs Group boosted their target price on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Wells Fargo & Company decreased their price target on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating for the company in a report on Friday, February 20th. Finally, Bank of America set a $203.00 price objective on Insmed in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.